More on China Cord Blood earnings

• China Cord Blood (NYSE:CO) posts a mixed FQ1, beating on its EPS but missing slightly on top line revenue.
• Total sales increased by 11.6% Y/Y, driven by higher storage fees.
• Accumulated subscriber base grew to 327,242, +27.7% year-over-year.
• Gross margin increased to 81% from 78.9% in the prior year period.